Within the realm of bodybuilding, an array of pharmaceuticals claims to combat stubborn fat. Today, let’s delve into Tesamorelin (Egrifta), an FDA-approved medication designed specifically for reducing abdominal fat – challenging the notion that spot reduction is an impossibility. Who says you can’t, right? (It appears RedStar may have alluded to this previously, a bit of a contradiction perhaps). Tesamorelin is specifically tailored for the task of trimming abdominal fat.
To begin, let’s explore Tesamorelin’s origin. It’s an FDA-approved drug employed for mitigating visceral and abdominal fat accumulation in HIV patients. Its mechanism involves stimulating the pituitary gland to increase the secretion of human growth hormone (GH). In essence, it functions as a growth hormone-releasing factor. While sharing similarities with previously mentioned compounds like CJC-1295DAC and GHRP, Tesamorelin stands on its own.
Addressing HIV may evoke apprehension, given the severity of AIDS. However, medications utilized by HIV patients tend to prioritize safety due to their weakened immune systems, necessitating medications with a heightened safety profile compared to those for the general populace. Currently, Tesamorelin holds approval solely for addressing abdominal fat accumulation linked to HIV. Its predominant application lies in promoting cardiovascular health.
Tesamorelin is presented in lyophilized powder form, necessitating reconstitution with sterile water before use. The recommended daily dosage is 2mg, administered through injection into the region of abdominal fat accumulation (as opposed to directly into the muscle). A notable benefit of Tesamorelin usage is the ability to maintain abdominal tightness even with a less-than-ideal dietary regimen. As for side effects, occasional redness and swelling at the injection site have been reported, with minimal additional adverse effects. The overall side effect profile is deemed quite modest.
However, despite the positive aspects, Tesamorelin is regrettably not readily available on the market, especially not through unofficial channels. This scarcity may be attributed to its high production costs, yielding minimal profit margins. As far as RedStar’s latest information indicates, German-based EMD Serono Inc. is the exclusive manufacturer of this medication. Even if there were a direct pathway to acquire Tesamorelin from EMD Serono Inc., the monthly cost is estimated to hover around $3000 USD. Consequently, the financial investment is substantial. Nevertheless, for individuals legitimately diagnosed with HIV, accessing Tesamorelin through hospital channels proves to be a more economically viable option.
